Least developed countries vs Naoero: Immunization, Hib3
Least developed countries
74.4%
in 2024
Naoero
97.0%
in 2024
Least developed countries rank
30th
Naoero rank
29th
Immunization, Hib3 over time
- Least developed countries
- Naoero
How they compare
Naoero currently reports 97.0% against 74.4% in Least developed countries, a difference of 22.6%.
That makes Naoero's figure about 1.3 times Least developed countries's.
Across all 16 years both countries report, Naoero has been ahead every year.
Least developed countries ranks 30th and Naoero ranks 29th of 43 groups.
Naoero has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Least developed countries | Naoero | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 67.2% | 99.0% | 31.8% | Naoero |
| 2010s | 75.5% | 92.0% | 16.5% | Naoero |
| 2020s | 74.4% | 96.8% | 22.4% | Naoero |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Least developed countries or Naoero?
- Naoero, at 97.0% against 74.4% in Least developed countries as of 2024.
- What is the difference in immunization, hib3 between Least developed countries and Naoero?
- 22.6%, with Naoero ahead.
- How many years of comparable data are there for Least developed countries and Naoero?
- 16 years are reported by both, from 2009 to 2024.
- How do Least developed countries and Naoero rank globally for immunization, hib3?
- Least developed countries ranks 30th and Naoero ranks 29th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.